The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy
The efficacy of 5-fluorouracil-folinic acid chemotherapy (5-FU-FA) for the treatment of advanced colorectal cancer is widely accepted [1, 2] However progression with 5-FU-FA refractory disease is a serious and inevitable development Although the role of second line treatment with innotecan is proven [3, 4] , funding difficulties in the UK mean that many patients are offered best supportive care only, with consequently poor survival. Our aim in this brief report is to summarize our experience of adding mitomycin C to an infusional 5-FU-FA regimen in patients either with progressive or stabilised disease after an initial exposure to chemotherapy Mitomycin C is a natural product, isolated from Streptomyces caespitosus It acts as a bifunctional alkylating agent, and is preferentially activated in hypoxic regions It also appears to have some free radical action It is active against adenocarcinomas of the stomach, pancreas, colon and breast The dose limiting toxicity is haematological and in particular thrombocytopaema can be severe with a nadir of up to eight weeks
The use of mitomycin C as second line treatment in this context has been investigated with differing results Initial reports were promising [5, 6] , two abstracts in 1997 reporting the success of mitomycin C as salvage treatment for advanced colorectal cancer either with 5-FU, and alone Since then authors have published conflicting opinions Some have argued that it is a low cost, well-tolerated alternative, with acceptable efficacy when compared to other second line treatments, although it does not offer any survival advantage [7] [8] [9] Other authors have found it to be an unacceptable alternative offering no benefits to the patient over best supportive care, although the regimens compared have often differed in important ways [10, 11] We treated a total of 31 patients with advanced colorectal cancer who had either stable disease (n = 5) or progression (n = 26) on a regimen of infusional I v 5-FU (400 mg/m 2 I v bolus followed by 2800 mg/m 2 48-hour venous infusion) and FA (350 mg i v 2-hour infusion) between November 1998 and May 2000 This regimen was continued on a fortnightly basis with the same doses of 5-FU-FA and MMC added at a dose of 6 mg/m 2 , given immediately after the two-hour folinic acid infusion, as a bolus, once every 28 days Response was assessed by CT scanning and CEA estimation after every six cycles (i e , 3 doses of MMC) If disease remained stable or better on review, a further 6 cycles were offered fortnightly until 12 cycles (6 months), thereafter, the patient was given the option of continuing on monthly treatments or stopping
In total 204 treatment episodes were administered Three patients (97%) had partial responses judged on their CT scans, with mean time to progression of thirty-seven weeks A total of eight patients (25.8%) achieved disease stabilisation that lasted more than three months This gives a total of 11 patients with stable disease or better (35 5%, a 95% confidence interval (CI) of 18 2%-52 8%) For these patients, the mean time to progression was 33 weeks The remaining 20 patients progressed Of the five patients who had stable disease when MMC was added, one had a partial response, and two continued with stable disease Toxicity was not a major problem, even in this heavily pretreated group of patients Four patients had toxicity of grade 3 or above (13%) One suffered stomatitis (grade 3), two had neutropaenia (one febrile, both grade 3) and one had delayed thrombocytopaema (grade 3) There were no toxic deaths In total 88% of the planned chemotherapy dose was delivered Nine patients had died by May 2000. six of whom died within one year of commencing treatment This is a oneyear survival or 80.6% (95% CI 66 4%-94.9%), which compares favourably with other second-line treatments Overall we would conclude that the addition of MMC to 48-hour infusional 5-FU-FA chemotherapy for advanced colorectal cancer is well tolerated and has comparable activity to other second line agents We found a PR rate of 9 7%. and a SD rate of 25 8% Other recent studies have reported 12% and 30% respectively in similar circumstances [7] , This compares favourably with the results of other second line salvage regimens [3, 4] In addition mitomycin C is well tolerated, less costly and should be considered for inclusion in trials of polychemotherapy for advanced colorectal cancer 
